Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis
06 janv. 2023 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
As previously reported, resmetirom demonstrated improvements in NASH and liver fibrosis on liver biopsies, the primary endpoints of the MAESTRO-NASH trialA supportive analysis using consensus reads of...
DelveInsight Evaluates a Robust Nonalcoholic Fatty Liver Disease Pipeline as 110+ Influential Pharma Players to Set Foot in the Domain
02 janv. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Jan. 02, 2023 (GLOBE NEWSWIRE) -- DelveInsight Evaluates a Robust Nonalcoholic Fatty Liver Disease Pipeline as 110+ Influential Pharma Players to Set Foot in the Domain Nonalcoholic...
Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program
21 déc. 2022 16h15 HE
|
Madrigal Pharmaceuticals, Inc.
$259 Million in Equity Securities Sales and $50 Million in Additional Debt Financing CapacityMadrigal intends to submit a new drug application for resmetirom in the first half of 2023 CONSHOHOCKEN,...
Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis
19 déc. 2022 07h00 HE
|
Madrigal Pharmaceuticals, Inc.
In MAESTRO-NASH, a 52-week serial liver biopsy Phase 3 study in more than 950 patients, resmetirom achieved both primary endpoints and potentially clinically meaningful effects with both daily oral...
Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NASH Study of Resmetirom on Monday, December 19th
18 déc. 2022 16h00 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Dec. 18, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal Pharmaceuticals Provides an Overview of Upcoming Resmetirom Data Presentations and Reports 2022 Third Quarter Financial Results
03 nov. 2022 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
Two resmetirom oral abstracts to be presented at the AASLD Liver Meeting®: Phase 3 MAESTRO-NAFLD-1 data demonstrate the potential of resmetirom for the treatment of patients with compensated NASH...
NASH kNOWledge Adds David Garcia, PhD as New Board Member
13 sept. 2022 09h00 HE
|
NASH kNOWledge
PITTSBURGH, Sept. 13, 2022 (GLOBE NEWSWIRE) -- As NASH kNOWledge celebrates its fourth year helping to spread education and awareness about nonalcoholic fatty liver disease, it has a couple of...
Madrigal Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
07 sept. 2022 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis
31 août 2022 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results
04 août 2022 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
Madrigal remains on track to announce topline data from the Phase 3 MAESTRO-NASH biopsy study in the fourth quarter CONSHOHOCKEN, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals,...